- Home
- BLUE vs ARMP Comparison
BLUE vs ARMP Comparison
Compare BLUE & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLUE
- ARMP
- Stock Information
- Founded
- BLUE 1992
- ARMP N/A
- Country
- BLUE United States
- ARMP United States
- Employees
- BLUE N/A
- ARMP N/A
- Industry
- BLUE Biotechnology: Biological Products (No Diagnostic Substances)
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BLUE Health Care
- ARMP Health Care
- Exchange
- BLUE Nasdaq
- ARMP Nasdaq
- Market Cap
- BLUE 78.7M
- ARMP 80.0M
- IPO Year
- BLUE 2013
- ARMP N/A
- Fundamental
- Price
- BLUE $8.50
- ARMP $1.90
- Analyst Decision
- BLUE Hold
- ARMP Strong Buy
- Analyst Count
- BLUE 9
- ARMP 1
- Target Price
- BLUE $49.14
- ARMP $7.00
- AVG Volume (30 Days)
- BLUE 729.7K
- ARMP 9.8K
- Earning Date
- BLUE 11-14-2024
- ARMP 11-13-2024
- Dividend Yield
- BLUE N/A
- ARMP N/A
- EPS Growth
- BLUE N/A
- ARMP N/A
- EPS
- BLUE N/A
- ARMP N/A
- Revenue
- BLUE $53,120,000.00
- ARMP $5,467,000.00
- Revenue This Year
- BLUE $152.71
- ARMP N/A
- Revenue Next Year
- BLUE $233.91
- ARMP $83.33
- P/E Ratio
- BLUE N/A
- ARMP N/A
- Revenue Growth
- BLUE 144.50
- ARMP 34.92
- 52 Week Low
- BLUE $5.80
- ARMP $1.89
- 52 Week High
- BLUE $38.40
- ARMP $4.48
- Technical
- Relative Strength Index (RSI)
- BLUE 50.43
- ARMP 35.02
- Support Level
- BLUE $5.97
- ARMP $1.89
- Resistance Level
- BLUE $9.75
- ARMP $2.03
- Average True Range (ATR)
- BLUE 2.04
- ARMP 0.12
- MACD
- BLUE 0.07
- ARMP -0.03
- Stochastic Oscillator
- BLUE 26.83
- ARMP 2.44
About BLUE bluebird bio Inc.
bluebird bio Inc is a biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The Company operates in a single segment, focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases.
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.